Real-Life Experiences with Telaprevir in the Treatment of Chronic Genotype 1 Hepatitis C — The TEPS Study

As one of the first Direct Acting Antivirals (DAA), the protease inhibitor Telaprevir (TVR) was available in the European Union from 9/2011 until 9/2016 as a new treatment option for chronic Hepatitis C.

Aim. To assess the implementation of therapy stopping rules or shortening of the treatment and their impact on sustained virological response (SVR), as well as the safety and efficacy of the TVR-based therapy during routine daily treatment of patients in Germany.

Materials and Methods. 802 patients were assessed (272 treatment naïve, 520 pre-treated) in the noninterventional, multi-center study.

Results. 56.6 % of the patients achieved SVR. SVR rate was higher in patients with relapse after previous treatment (68.0 %) than in patients with a previous null-response (31.1 %) and in previously untreated patients (58.1 %). Stopping rule conditions were fulfilled by 3.2 % of patients and it was implemented in 65.4 % of these. 34.3 % of the patients fulfilled the conditions for a therapy shortening. This rule was adhered to in 48.4 % of these, in 34.5 % it was not adhered to. Thus recommendations were not always being followed. Therapy shortening was considered more frequently in previously untreated (54.8 %) than for previously treated patients (24.2 %). Stopping rule application but not shortened treatment reduced therapy costs.

Conclusion. The TVR-based therapy represented a breakthrough at that time. Further DAAs have been added as therapeutic options since, increasing the complexity of treatment choice and correct implementation. They represent both an opportunity and a challenge for all those involved.

As one of the first Direct Acting Antivirals (DAA), the protease inhibitor Telaprevir (TVR) was available in the European Union from 9/2011 until 9/2016 as a new treatment option for chronic Hepatitis C.Aim. To assess the implementation of therapy stopping rules or shortening of the treatment and their impact on sustained virological response (SVR), as well as the safety and efficacy of the TVR-based therapy during routine daily treatment of patients in Germany.Materials and Methods. 802 patients were assessed (272 treatment naïve, 520 pre-treated) in the noninterventional, multi-center study.Results. 56.6 % of the patients achieved SVR. SVR rate was higher in patients with relapse after previous treatment (68.0 %) than in patients with a previous null-response (31.1 %) and in previously untreated patients (58.1 %). Stopping rule conditions were fulfilled by 3.2 % of patients and it was implemented in 65.4 % of these. 34.3 % of the patients fulfilled the conditions for a therapy shortening. This rule was adhered to in 48.4 % of these, in 34.5 % it was not adhered to. Thus recommendations were not always being followed. Therapy shortening was considered more frequently in previously untreated (54.8 %) than for previously treated patients (24.2 %). Stopping rule application but not shortened treatment reduced therapy costs.Conclusion. The TVR-based therapy represented a breakthrough at that time. Further DAAs have been added as therapeutic options since, increasing the complexity of treatment choice and correct implementation. They represent both an opportunity and a challenge for all those involved.

Hepatitis C, Direct Acting Antivirals (DAA), stopping rule, shortening of treatment, Sustained virological response (SVR)

1. Robert-Koch-Institut. Virushepatitis C im Jahr 2013. Epidemiologisches Bulletin. 2014;31:275–88. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2014/Ausgaben/31_14.pdf?__blob=publicationFile

2. Hüppe D., Zehnter E., Mauss S., Böker K., et al. Epidemiology of chronic hepatitis C in Germany-an analysis of 10,326 patients in hepatitis centres and outpatient units (in German). Z Gastroenterol. 2008;46(1):34–44. DOI: 10.1055/s-2007-963691

3. Sarrazin C., Berg T., Ross R.S., Schirmacher P., et al. Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection (in German). Z Gastroenterol. 2010;48(2):289–351. DOI: 10.1055/s-0028-1110008

4. McHutchison J.G., Lawitz E.J., Shiffman M.L., Muir A.J., et al. Peg Interferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580–93.

5. Herber A., Berg T. Hepatitis C — neue Behandlungen. MedWelt. 2011;62:119–31.

6. Jacobson I.M., McHutchison J.G., Dusheiko G., Di Bisceglie A.M., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med.2011; 364(25):2405–16.

7. Sherman K.E. Flamm S.L., Afdhal N.H., Nelson D.R., et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365(11):1014–24.

8. Trembling P.M., Tanwar S., Rosenberg W.M., Dusheiko G.M., et al. Treatment decisions and contemporary versus pending treatments for hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10(12):713–28.

9. Sarrazin C., Berg T., Cornberg M., Dollinger M., et al. Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C (in German). Z Gastroenterol. 2012;50(1):57–72.

10. Mauss S., Böker K., Buggisch P., Christensen S., Hofmann W. P., Schott E., Pfeiffer-Vornkahl H., Alshuth U. Hüppe D. Real-life experience with first generation HCV protease inhibitor therapy in Germany: The prospective, noninterventional PAN cohort. Z Gastroenterol. 2015;53(7):644–54.

11. Zeuzem S. Andreone P., Pol S., Lawitz E., et al. Telaprevir for Retreatment of HCV Infection. N Engl J Med. 2011;364(25):2417–28.

12. Klass D.M., Hinrichsen H., Boeker K.H., et al. Hepatitis C Population in Germany, Changing over Time. Poster presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, USA, 2012.